The abstract is read at the publisher; the summary is JClub's.
SIRPαD1-αPCSK9 fusion protein co-targeting CD47-SIRPα and the PCSK9–MHC-I axis reprograms tumor macrophages to enable durable antitumor immunity.
- Why it matters: Macrophage checkpoint blockade can clear tumors but often fails to sustain effective T cell responses, indicating a disconnect between innate phagocytosis and adaptive priming.
- What they did: The study identifies PCSK9 as an adaptive resistance factor induced by macrophage checkpoint blockade, showing tumor-derived PCSK9 drives lysosomal degradation of MHC-I in macrophages and reduces antigen cross-presentation. It then engineers bispecific fusions, with SIRPαD1-αPCSK9 as optimal, to dual-target the CD47-SIRPα checkpoint and the PCSK9–MHC-I axis.
- The result: Dual targeting synergistically enhances phagocytosis, preserves antigen cross-presentation, and shifts the tumor microenvironment toward an immunostimulatory state, yielding potent tumor control with improved safety.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.